VTRS Viatris Inc.
Viatris Inc., together with its subsidiaries, operates as a healthcare company in North America, Europe, China, Taiwan, Hong Kong, Japan, Australia, New Zealand, rest of Asia, Africa, Latin America, and the Middle East. It operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. The company offers prescription brand drugs, generic drugs, complex generic drugs, and biosimilars. It also provides drugs in various therapeutic areas covering various noncommunicable and infectious diseases, including cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, eye care, gastroenterology, immunology, oncology, and respiratory and allergy, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. In addition, the company offers medicines in the form of oral solid doses, injectables, and complex dosage forms to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. It distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies under the Lyrica, Lipitor, Celebrex, Viagra, Creon, Influvac, Wixela Inhub, EpiPen Auto-Injector, Fraxiparine, Yupelri, Norvasc, Amitiza, Effexor, Lipacreon, Zoloft, Xalabrands, Dymista, Xanax, and Breyna brands. The company has collaboration agreements with Mapi Pharma Ltd. to develop and commercialize long-acting glatiramer acetate depot products and additional products; Revance Therapeutics, Inc. to develop, manufacture, and commercialize a biosimilar to the branded biologic product, BOTOX; and Theravance Biopharma, Inc. to develop and commercialize revefenacin. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.…
Industry Peers
Drug Manufacturers - Specialty & GenericKey Statistics
About Viatris (NASDAQ: VTRS)
›
Viatris (NASDAQ: VTRS) is listed on Nasdaq, where its shares trade in USD. It belongs to the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector, and reports about 30,000 employees.
The shares were at 19.88 USD on 19 November 2026, up 90.1% over 52 weeks. Its 52-week range is 9.920 USD to 21.20 USD: the price is 6.2% below the high and 100.4% above the low.
Its market capitalisation is 22.79B USD. It pays a dividend yielding 2.37%, against a median of 1.88% among the dividend payers in that peer group.
Viatris reports return on equity of -23.9%, an operating margin of 11.5% and flat revenue year over year.
Its debt exceeds its cash by 11.57B USD, a debt-to-equity ratio of 1.00. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 10 analysts cover the stock, with an average rating of Buy; their mean price target of 21.60 USD is 8.7% above the current price. The next earnings report is expected on 25 February 2027.